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he Timing for Transplantation
uperior Genetics or Social Prejudice?*
avid Feldman, MD, PHD, FACC
olumbus, Ohio
n this issue of the Journal, Elmariah et al. (1) bring forward
provocative and potentially contentious idea—that men
nd women are not the same and should be treated
ifferently. Specifically, these investigators assert that for
atients with advanced heart failure who may require a
ransplant, there should be different objective criteria for
etermining when a patient should undergo transplantation
ased on the patient’s gender. The application of the
nvestigators’ conclusion would suggest that women are
ither genetically superior, possess different myocyte trans-
uction mechanisms to compensate for the same degree of
eart failure (1), or should receive inferior health care based
n a number (metabolic stress test). The danger of this
umber is that it was derived from a single-center retro-
pective database and from a relatively small number of
atients. More importantly, neither the investigators nor I
nderstand the mechanism for the observed difference. This
See page 2237
akes the results an observation, not an irrefutable fact. The
anger in accepting the results in this study is not the
alidity of the observations, but the potential application of
his study to clinical practice without the understanding of
mechanism. Potentially, the results might be applicable to
linical practice if they had been substantiated by a prospec-
ive randomized trial. This would not likely provide the
echanistic data required to understand the observations
ut forward in this article, but it would provide additional
upport for a meaningful concept that may take physicians
ears to understand, or possibly may never be understood.
lthough this is easy for me to request, it is far more
ifficult to orchestrate in clinical practice. An internal review
oard would certainly pronounce that such a study was
nethical because it discriminates against a preselected
roup of patients. Of course, the only end point that would
ddress the issues in the paper would be all-cause and
ardiovascular mortality, with everything else perceived as
upportive or damning evidence for this single assertion.
herefore, clinicians and scientists find themselves at an
mpasse. If you do not apply the results of this article to
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Heart Failure and Cardiac Transplantation Departments of Medicine/s
ardiology, Physiology, and Cell Biology, The Ohio State University, Columbus,
hio.linical practice, and there may never be a prospective
andomized control trial, where are we with the concerns
ut forth by these investigators?
To state the obvious, all papers have their shortcomings
nd strengths. Many of the limitations of this specific study
ave been enumerated by the investigators in the discussion
ection of the article. As such, it would be redundant to
ecapitulate those issues again. However, there are a few
dditional concerns worth considering in a critical review of
his well-constructed analysis: 1) It would be overly simplis-
ic to suggest that any patient should or should not undergo
ransplantation based on any number. 2) The women in this
tudy were younger than the men and had higher ejection
ractions, and variables such as New York Heart Association
unctional class, standardization of the exercise protocol,
rior exercise conditioning, and renal function were all
nknown. All of these variables have been known to impact
ortality in heart failure; hence, it is plausible that some of
hese variables may have confounded the results of this
tudy. In addition, although there were an equal number of
atients using beta-blockers, the dose that may affect
ortality (1) for any given patient was unknown (control-
ing for heart rate may not be sufficient). 3) As a final
oncern, the percentage of patients who were women in this
tudy was 28% of the total population analyzed; this may
uggest a selection bias.
In contrast to these concerns, this article also has some
nique features worthy of mention. Further analysis from
hese investigators showed that patients who had achieved
naerobic threshold (by respiratory exchange ratio or
-slope methodology) still had a similar disparity with
oncordant results from the published article. In addition,
67 women from diverse backgrounds were represented in
his single-center study. This represents the largest number
f women studied in this setting, albeit not a huge number.
urthermore, these investigators did account for some of the
ost probable confounding variables, including lung func-
ion, baseline medications (but not doses), age, race, diabetes,
ypertension, atrial fibrillation, and heart failure etiology.
Unfortunately, the conundrum of how to interpret these
esults becomes even more complicated when one reflects on
his subject for another moment. Investigators use statistical
nalysis as one of our most important tools for determining
he relevance of a specific finding, but regrettably standard
tatistical analysis can fail any investigator with the best of
ntentions. Examples may include a statistically relevant
value with a result that may not be clinically significant or
he relevance of the p value of 0.05 or 0.01 in any specific
tudy. That is, these p values would suggest that an
nvestigator would come to the same conclusion 95 or 99 of
00 times, or in the current study, 999 of 1,000 times. In
any studies, investigators power their statistics for a
pecific outcome with hundreds or thousands of patients. In
uch a case, perhaps a p value 0.053 may be clinically
ignificant and not statistically significant. Furthermore, if a
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Editorial Comment June 6, 2006:2243–4rial has a total of 10 patients and there is a difference
etween groups with a p value of 0.001, the validity of the
esults would certainly require a larger study with power
alculations, and an advisory panel. In contrast to patients
efore transplantation, women after transplantation may
ave a higher risk of death compared with men. Statistics
uggest that women have a 5% higher rejection rate than
en in the first year, and are a greater risk of death by
enerally having a higher antigen profile and being of
horter stature. These three findings are all associated with
igher death rates with statistically significant p values.
urther analysis of the results suggests that women have a
ve-year mortality rate that is 13% higher than that for men
ith a p value of 0.02 with a very large number of patients,
ut at the end of multivariate analysis and conditional
odeling, these variables do not suggest that women are
isadvantaged (4). This illustration may suggest that we
nconsciously may perceive a given result or data set to fit
ur biases.
One of the most important contributions of this article is
eflection on the larger questions that these investigators
ere attempting to address. One of the statistical assertions
f this article is that patients should not undergo transplan-
ation (or possibly receive heroic therapies) if they only have
15% chance of dying in a one-year period. This is a
ortality rate that would not be well tolerated for many
ther disease processes. Today, with such a devastating
ortality rate for heart failure patients, we must consider
hether we are asking the right questions, or whether we
ave become too comfortable with our current understand-
ng of heart failure mechanisms, pathophysiology, and
herapeutics. Perhaps we do have some of the correct
edications and are using them in the wrong patients. Case
n point, the one-year mortality rate for an acutely decom-
ensated patient is increased with a hospital admission (5),
nd the hospital five-year mortality rate in many studies
ontinues to be 50% (6). In addition, the investigators haveroposed MVO2 cutoff levels that are substantially lower
han those currently used by many transplantation centers.
he Elmariah et al. (1) paper focuses our attention on
onsidering whether there is a general need to reassess the
riteria for transplantation in the modern era of new medical
herapies and mechanical device technology. The inferred
ubtext of this suggestion is that we may be performing
ransplantations unnecessarily or prematurely and thereby
quandering a very limited resource. This paper forces us to
hink about uncomfortable issues such as how we interpret
ur current practice, what we do not know, and how much
urther we have to go (2,3).
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